Insulin Resistance & Metabolic Health

Written by Empire Medical Training Editorial Team

Medically reviewed by Faride Ramos, MD Double Board-Certified, Internal & Functional Medicine; Functional Endocrinology

Updated June 2026 ·11 min read

Insulin resistance is one of the most consequential and most overlooked findings in adult medicine. By the time a fasting glucose or hemoglobin A1c finally rises into a diagnosable range, the underlying process has usually been running for years — silently storing fat in the midsection, sapping energy, and nudging blood pressure and lipids in the wrong direction. A functional medicine lens asks the upstream question earlier: why are these cells no longer listening to insulin, and what is the system trying to tell us?

This guide is clinical education for providers, not medical advice for patients, and nothing here is a protocol or a substitute for individualized care. The aim is to give a clear, honest picture of insulin resistance, situate it within the hormone “symphony” that defines functional endocrinology, and connect it to the broader cardiometabolic story.

What is insulin resistance?

Insulin is the body's primary storage and growth signal. After a meal, the pancreas releases insulin to move glucose out of the bloodstream and into cells, where it is burned or stored. In insulin resistance, the cells stop responding efficiently to that signal. Glucose lingers, so the pancreas does the only thing it can: it secretes more insulin to force the message through. For a long while this compensation works — blood sugar stays in range — but at the cost of chronically elevated insulin, a state called hyperinsulinemia.

That distinction matters clinically. Because insulin itself is a fat-storage and anti-lipolysis signal, persistently high insulin keeps the body in storage mode: it favors fat deposition (especially in the abdomen), suppresses fat breakdown, and contributes to the fatigue and stubborn weight that patients describe long before any lab is flagged abnormal. Only when the pancreas can no longer keep up does glucose finally rise — which is why fasting glucose and A1c tend to confirm the problem late rather than catch it early.

This is precisely the gap a root-cause approach is built to close. Rather than waiting for a number to cross a population-defined threshold, the functional question is whether this individual is already drifting toward metabolic trouble, and what is driving it. Empire's faculty frame it bluntly: standards tell you what is typical for a population, not what is optimal for the patient in front of you, who has their own physiology and their own fingerprints.

Insulin and the hormone symphony

One of the central teaching points in functional endocrinology is that hormones never act alone — they are, in Dr. Faride Ramos's framing, a symphony that begins with cortisol, runs through thyroid, and extends to the sex hormones. Insulin sits inside that symphony, and it cannot be understood in isolation from the others.

The clearest example is cortisol. Cortisol is a stress hormone whose job, in part, is to raise blood sugar — it drives gluconeogenesis and increases circulating glucose to fuel a perceived threat. That is adaptive for a short, acute stressor. But under chronic stress — poor sleep, relentless workload, modern always-on life — cortisol keeps nudging glucose up, which forces the pancreas to keep releasing insulin, which deepens insulin resistance over time. Chronically elevated cortisol also preferentially deposits fat in the visceral adipose tissue of the midsection, the very fat depot most strongly tied to metabolic risk. Stress, blood sugar, and belly fat are not three separate problems; they are one feedback loop. (The cortisol side of that loop is explored in depth in cortisol and chronic stress.)

The sex hormones interact as well. In PCOS, insulin resistance and excess androgens reinforce each other; high insulin can drive ovarian androgen production, and excess adipose tissue raises aromatase activity, shifting the androgen-to-estrogen picture. In midlife, the changing estrogen-to-progesterone balance of perimenopause coincides with new central weight gain and worsening insulin sensitivity. None of this is captured by a glucose number alone, which is why functional endocrinology assesses metabolic health alongside the adrenal and sex-hormone picture — the subject of functional endocrinology and hormone imbalance.

Metabolic syndrome: the cluster that matters

Insulin resistance rarely shows up as a single finding. It tends to announce itself as a cluster, and that cluster has a name: metabolic syndrome. It is diagnosed when a patient meets at least three of five criteria:

• Increased waist circumference — central, visceral adiposity rather than total body weight.
• Elevated triglycerides.
• Low HDL cholesterol.
• Elevated blood pressure.
• Elevated fasting glucose.

The reason the cluster matters more than any single line on the panel is that it identifies a patient who is on a cardiometabolic trajectory — at meaningfully higher risk for type 2 diabetes and cardiovascular disease — well before frank diabetes appears. Insulin resistance is widely regarded as the common thread tying these five findings together: the same hyperinsulinemia that stores visceral fat also tends to raise triglycerides, lower HDL, and contribute to higher blood pressure. Recognizing the pattern, rather than treating five disconnected numbers, is the whole point.

Early markers worth thinking about

If fasting glucose and A1c rise late, what can flag the problem earlier? Several markers are useful as concepts for thinking upstream — not as a turnkey panel to reflexively order on everyone:

• Fasting insulin. Because hyperinsulinemia precedes hyperglycemia, an elevated fasting insulin can reveal compensation that glucose still hides.
• HOMA-IR. A calculation derived from fasting glucose and fasting insulin that estimates insulin resistance, useful for tracking a trajectory over time.
• Triglyceride-to-HDL ratio. A widely discussed surrogate that often tracks with insulin resistance and is available on a standard lipid panel.
• Waist circumference. A simple, no-cost measure of the central adiposity that drives the syndrome.

An honest caveat belongs here. “Optimal” versus laboratory reference ranges, and the interpretation of these surrogates, are areas where functional and mainstream practice sometimes diverge, and the appropriate cutoffs are debated. The disciplined principle — one Empire's faculty emphasize — is that testing should answer a specific clinical question, not fish for something to treat. A marker is a prompt for judgment and proper follow-up, not a diagnosis by itself. The full philosophy of when and what to test is covered in functional medicine lab testing.

The root-cause, lifestyle-first approach

Here is the genuinely hopeful part: insulin resistance is frequently responsive to lifestyle. That is why a root-cause approach puts foundational behaviors first — before, and often alongside, any pharmacology — rather than reaching immediately for a prescription to manage a number while the upstream cause keeps running.

Four levers do most of the work, and notably they are the same four that govern the rest of the hormone symphony:

• Nutrition. Reducing refined and high-glycemic carbohydrates lowers the repeated glucose-and-insulin surges that entrench resistance. Empire's faculty are explicit that a diet rich in simple, refined carbohydrates is itself a chronic stressor on the system.
• Movement. Both resistance training and aerobic activity improve glucose uptake by muscle and increase insulin sensitivity — arguably the most direct non-pharmacologic lever available.
• Sleep. Restorative sleep restrains the cortisol drive that keeps blood sugar elevated; poor sleep does the opposite and worsens next-day glucose handling.
• Stress reduction. Lowering chronic cortisol output through deliberate practices eases one of the strongest drivers of visceral fat and insulin resistance.

Because metabolic health is so tightly bound to what a patient eats and how their weight is managed, this work overlaps directly with two adjacent pillars: medical weight loss, where insulin resistance is the central metabolic target, and precision nutrition, which translates the nutrition lever into individualized practice. A functional approach treats these not as separate services but as one coordinated plan.

An honest word on medication

Lifestyle-first does not mean lifestyle-only, and it is important not to overpromise. Medication has a real and legitimate place in metabolic care. Some patients present with established type 2 diabetes, advanced metabolic syndrome, or risk profiles where waiting on lifestyle alone would be poor medicine; for them, pharmacologic therapy — including the GLP-1 receptor agonists now central to medical weight loss — can be exactly the right tool. The functional position is not anti-medication; it is anti-reflex. The goal is to fix the root cause where it can be fixed and to use pharmacology deliberately, as a tool rather than a default.

The same balance applies to the broader hormonal picture. Where a genuine hormone deficiency is part of the metabolic story, replacement may be appropriate — but that is a distinct decision with its own evidence, regulatory nuance around bioidentical and compounded preparations, and monitoring requirements, addressed separately under hormone replacement rather than prescribed off a metabolic page. The honest, defensible stance is to match the intervention to the patient.

Safety, scope, and red flags

This is clinician education, not a patient self-treatment guide, and metabolic and hormonal conditions require proper diagnosis, monitoring, and — when indicated — referral. Several situations warrant prompt and appropriate medical work-up rather than a lifestyle plan alone: markedly elevated glucose or A1c, symptoms suggesting new or poorly controlled diabetes, severe or rapidly progressive symptoms, pregnancy or planned pregnancy, and a personal or family history of cardiac or cancer disease that changes the risk calculus. Hormone-modifying decisions in particular demand baseline assessment, individualized dosing, and follow-up under a qualified clinician.

Insulin resistance is best understood as a systems problem with a hopeful prognosis — addressable, but only when it is recognized early, framed within the whole hormone symphony, and managed with judgment rather than reflex. That integrated, root-cause skill set is exactly what structured functional-medicine training is built to teach.